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Because of its ability to regulate the abundance of selected proteins the ubiquitin
proteasome system (UPS) plays an important role in neuronal and synaptic plasticity.
As a result various stages of learning and memory depend on UPS activity. Drug
addiction, another phenomenon that relies on neuroplasticity, shares molecular substrates
with memory processes. However, the necessity of proteasome-dependent protein
degradation for the development of addiction has been poorly studied. Here we first
review evidences from the literature that drugs of abuse regulate the expression and
activity of the UPS system in the brain. We then provide a list of proteins which have
been shown to be targeted to the proteasome following drug treatment and could thus
be involved in neuronal adaptations underlying behaviors associated with drug use and
abuse. Finally we describe the few studies that addressed the need for UPS-dependent
protein degradation in animal models of addiction-related behaviors.
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THE UBIQUITIN PROTEASOME SYSTEM (UPS)
The role of protein turnover mediated by the ubiquitin protea-
some system (UPS) in neuronal plasticity and memory has been
studied for about two decades. Here we will only briefly summa-
rize the basic functioning of this system that has been described in
more detail in several reviews (Ciechanover, 2005; Patrick, 2006;
Hegde, 2010; Mabb and Ehlers, 2010; Bingol and Sheng, 2011).
The UPS controls the degradation of misfolded newly synthe-
sized proteins as well as the turnover of specific target proteins.
Its function can be described as a two-step process: the tagging
of target proteins and their degradation. Ubiquitin molecules
can be attached one to another and form a poly-ubiquitin chain
which acts as a specific tag to direct proteins to proteasome-
dependent degradation (Figure 1A). This enzymatic linkage is
dependent on the activity of three types of enzymes: Ubiquitin-
activating enzymes (E1), Ubiquitin-conjugating enzymes (E2),
and Ubiquitin ligases (E3). E1 enzymes form a thioester bond
with a ubiquitin molecule to activate it. The combined action
of E2 and E3 enzymes then permits its linkage to a specific
target protein. E3 enzymes mark the proteins that have to be
degraded with a poly-ubiquitin chain (linked through Lysine 48
residues) but can also mediate mono- or other types of poly-
ubiquinitation to affect different processes such as protein traf-
ficking and kinase activation (see Bingol and Sheng, 2011 for a
more detailed description). Another important class of enzymes
is also involved in the regulation of poly-ubiquitination and UPS
activity: the desubiquitinating enzymes (DUBs). They oppose the
action of E3 ligases by removing ubiquitin. Thus, E1, E2, E3, and
DUB enzymes tightly regulate the addressing of proteins to the
proteasome. The second step of UPS function relies on the prote-
olytic activity of the 26S proteasome. This complex of proteins
can be sub-divided into two components: the 20S proteasome
which is the catalytic core where degradation takes place and
the 19S proteasome which acts as a regulatory complex. The 20S
proteasome is made of two external and two internal rings of pro-
teins. External rings are composed of seven alpha type proteins
(numbered from α1 to α7). They are involved in the regulation
of the access of tagged proteins to the inner core (internal rings)
of the 20S proteasome. The internal rings are composed of seven
beta type proteins (numbered from β1 to β7) which are respon-
sible for the catalytic activity of the proteasome. Three subunits
are directly involved in degradation processes: the β1, β2, and
β5 subunits which are responsible for caspase-like, trypsin-like
and chymotrypsin-like activity respectively. The other types of
β subunits have been proposed to play a structural role in the
complex and to be involved in the binding of targeted proteins
during their degradation by β1, β2, and β5 subunits. Different
complexes can be associated with the 20S proteasome, the 19S
proteasome being the most frequent. The 26S proteasome pos-
sesses two 19S proteasome regulatory complexes located at each
extremity of the 20S core. They can also be divided in two dis-
tinct subparts: the lid and the base. The lid is composed by 9
regulatory particle non-ATPase (Rpn) proteins and possesses two
main roles: the recognition of poly-ubiquitinated proteins and the
removal of ubiquitin from the targeted proteins. The base is com-
posed of 10 proteins with or without ATPase activity, Regulatory
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FIGURE 1 | The Ubiquitin Proteasome System and its components
regulated after drug exposure. (A) Schematic representation of the
Ubiquitin Proteasome System. The external and internal rings constitute
the 20S proteasome. The lid and base constitute the 19S regulatory
complex. In some cases, it can be replaced by the PA28 or 11S
regulatory complex, constituted of a single ring of 7 subunits. (B)
Classification of the UPS components found to be regulated after drug
exposure.
particle ATPases (Rpt) and Rpn proteins respectively. It is phys-
ically connected to the proteasome 20S and is involved in the
unfolding of proteins and the regulation of their entry into the
catalytic core. Thanks to the combined actions of E1, E2, E3,
and DUB enzymes and the 19S proteasome complex, the UPS
can finely control the identity of the proteins to be targeted and
degraded by the catalytic core located in the inner part of the 20S
proteasome.
THE UPS IN NEURONAL PLASTICITY AND MEMORY
Changes in neuronal activity can result in the regulation of many
proteins by the UPS. A descriptive study showed that increases or
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decreases in the activity of cultured hippocampal neurons pro-
duce UPS-dependent changes in the amount of several proteins
in post-synaptic densities (PSD), including proteins involved in
PSD morphology, cytoskeleton organization and scaffolding of
signaling complexes (Ehlers, 2003). This result suggests a close
relationship between synaptic plasticity and protein degrada-
tion. Indeed, it has been reported that protein degradation by
the UPS contributes to the formation and maintenance of long-
term potentiation (LTP) and long-term depression (LTD). The
first study reporting this involvement was conducted in Aplysia
during induction of long-term facilitation (LTF) (Hegde et al.,
1993). It demonstrated that regulatory subunits of the Protein
kinase A (PKA) are targeted to the proteasome for degrada-
tion allowing prolonged action of PKA and Aplysia behavioral
sensitization (Hegde et al., 1993). Later on, studies in rodents
have shown that blocking the UPS in the hippocampus can
alter N-methyl-D-aspartate (NMDA)- and/or metabotropic glu-
tamate receptor (mGluR)-dependent LTD or LTP (Colledge et al.,
2003; Citri et al., 2009). This deleterious effect of UPS block-
ade on long term changes in neurons has been suggested to
be due to an alteration in the balance between protein synthe-
sis and degradation (Fonseca et al., 2006). Indeed the authors
showed that the deleterious effects produced by inhibiting either
protein synthesis or degradation on LTP can be reversed by inhi-
bition of the two processes at the same time. In addition to
synaptic proteins the UPS is also involved in the regulation of
the activity of transcription factors, thus revealing a close rela-
tionship between protein synthesis and proteasome action. For
example IκB and CREM (cAMP-responsive element modulator),
repressors of the transcription factors NF-κB and CREB (cAMP
response element binding) respectively, can be ubiquitinated and
degraded by the UPS (Woo et al., 2010; Liu and Chen, 2011).
In that sense the UPS clearly plays a major role in the regula-
tion of protein turnover implicated in neuronal plasticity acting
directly through the degradation of some proteins and indirectly
through the modulation of transcriptional activity and protein
synthesis.
Unsurprisingly considering its role in neuronal plasticity, a
strong involvement of UPS function has also been observed dur-
ing learning and memory processes. These results are reported in
detail in a recent review (Jarome and Helmstetter, 2014). More
than 10 years ago a first study demonstrated the role of the pro-
teasome in the dorsal hippocampus during the acquisition phase
of inhibitory avoidance memory (Lopez-Salon et al., 2001). In
this work the authors reported an increase in the rate of protein
poly-ubiquitination in the hippocampus during training. They
also found that the repressor of NF-κB, IκB, was present in this
poly-ubiquitinated protein pool showing an involvement of the
UPS in transcription factor activation. More recent studies con-
firmed the necessity of protein degradation in the hippocampus
during consolidation and reconsolidation processes in rodents in
spatial memory and fear conditioning (Artinian et al., 2008; Lee
et al., 2008). The hippocampus is not the only region were pro-
teasome activity is required for the creation and maintenance of
memory. The involvement of protein degradation in both the pre-
frontal cortex and the amygdala during fear learning has also been
demonstrated (Jarome et al., 2011; Reis et al., 2013). Proteasome
action also appears to be necessary in both the insular cortex and
the amygdala for aversive taste learning (Rodriguez-Ortiz et al.,
2011).
The precise mechanisms underlying the involvement of the
proteasome in memory are just beginning to be discovered but
it is now clearly established that, in addition to protein synthesis,
neuronal protein degradation by the UPS is a mandatory process
to create, store and maintain memories and in that sense partic-
ipates to adaptive behaviors of mammals. Since drug addiction
shares common mechanisms with memory processes (Hyman
et al., 2006; Milton and Everitt, 2012) it is important to question
the role of the UPS in the long term effects of drugs of abuse such
as opioids, stimulants, ethanol, nicotine and cannabinoids.
DRUGS OF ABUSE REGULATE THE UPS
In recent years, many transcriptomic and proteomic studies have
described the global effects of treatments with drugs of abuse
on the brain, or on neuronal or glial cell lines. Proteasome sub-
units or proteins involved in the ubiquitination process are often
found to be regulated in these studies (Table 1, Figure 1B). In
the case of opioids, it was shown in a cellular model that a
prolonged 72 h morphine treatment modifies the abundance of
two proteasome subunits (α3 and β6) (Neasta et al., 2006). In
vivo, intra-cerebro-ventricular (icv) infusion ofmorphine for 72 h
results in an increase in the tyrosine-phosphorylated form of the
β4 subunit in the rat frontal cerebral cortex (Kim et al., 2005).
A longer intermittent treatment (2 weeks) produces a decrease
in the amount of the DUB Ubiquitin C-terminal hydrolase L-1
in the nucleus accumbens (Nacc) (Li et al., 2006). 4 days after
morphine withdrawal, the quantity of this enzyme, as well as that
of the α3 subunit of the proteasome, increases in rat dorsal root
ganglia (Li et al., 2009). Similarly, chronic treatment (90 days)
and drug withdrawal have been shown to have opposite effects
on the amount of α5 subunit in the Nacc of rhesus monkeys (Bu
et al., 2012). The levels of Ubiquitin-conjugating enzyme E2 and
of Ubiquitin C-terminal hydrolase L-3 are also modulated in this
model. Finally, in a morphine-induced conditioned place pref-
erence (CPP) paradigm which tests the rewarding properties of
the drug, both development, extinction and re-instatement are
accompanied by a down-regulation of several DUBs and α and
β subunits (Lin et al., 2011).
Changes in expression of proteins of the UPS are not specific
to opioid treatment. The amount of Ubiquitin C-terminal hydro-
lase L-1 is increased and that of RN3 (β7 catalytic subunit) is
decreased in the striatum of rats acutely treated with metham-
phetamine while repeated injections induce an increase in
Ubiquitin C-terminal hydrolase L-1 and a decrease in several pro-
teasome subunits in the frontal cortex (Iwazaki et al., 2006; Faure
et al., 2009; Kobeissy et al., 2009). The development of cocaine
CPP comes with an increase in the expression of the Ubiquitin-
conjugating enzyme E2N, of the catalytic α2 subunit and of the
26S proteasome regulatory subunit p45/SUG (Guan and Guan,
2013). Moreover, mouse cortical neurons grown in the presence
of ethanol for 5 days show decreased amounts of mRNA coding
for several ubiquitin-conjugating enzymes, as well as catalytic and
regulatory subunits of the proteasome (Gutala et al., 2004) while
the quantities of Ubiquitin C-terminal hydrolase L-1 decrease and
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Table 1 | UPS-related molecular and cellular consequences of the treatment with drugs of abuse.
Drug class Drug Treatment Cell type/Species Molecular/cellular effects Reference
Opioids Morphine 72 h Recombinant SH-SY5Y
cells
Change in α3 and β6 subunit abundance Neasta et al., 2006
Morphine 24 h Recombinant SH-SY5Y
cells
UPS-dependent down-regulation of Gβ
subunits of heterotrimeric
G proteins
Mouledous et al.,
2005
DAMGO Overnight Human SH-SY5Y cells UPS-dependent down-regulation of
RGS4
Wang and Traynor,
2011
DADLE 40min Recombinant HEK
cells
MOP receptor ubiquitination Hislop et al., 2011
Basal turnover N.A. Recombinant NMB
cells
MOP receptor degradation by the UPS Song et al., 2009
Morphine 4 h and 24h Human SK-N-SM cells Modulation of proteasome catalytic
activity
Rambhia et al., 2005
Morphine 48 h Rat C6 glioma cells UPS-dependent down-regulation of
EAAC1 glutamate transporter
Yang et al., 2008b
Morphine 7 days intra-thecal Rat spinal cord UPS-dependent down-regulation of
EAAC1, GLAST, and GLT-1
glutamate transporters
Yang et al., 2008a
Morphine 72 h icv Rat frontal cortex Increase in Tyr-phosphorylated β4
subunit
Kim et al., 2005
Morphine 2 weeks Rat nucleus
accumbens
Decrease in Ubiquitin C-terminal
hydrolase L-1
Li et al., 2006
Morphine CPP Rat amygdala Decrease in α3, α6, β3, β4, β7 subunits,
Ubiquitin C-terminal
hydrolase L-1 and Ubiquitin specific
protease 7
Lin et al., 2011
Morphine 4 days after
withdrawal
Rat dorsal root ganglia Increase in Ubiquitin C-terminal
hydrolase L-1 and α3 subunit
Li et al., 2009
Morphine 4 days, increasing
doses
Mouse striatum Reduced UPS-dependent degradation of
HSP70
Yang et al., 2014
Morphine CPP Mouse Nacc
synaptosomes
Increase in total protein ubiquitination Massaly et al., 2013
Morphine 90 days Rhesus monkey Nacc Increase in α5 subunit and decrease in
Ubiquitin conjugating enzyme E2
Bu et al., 2012
Morphine Withdrawal Rhesus monkey Nacc Decrease in α5 subunit and increase in
Ubiquitin C-terminal hydrolase L-3
Bu et al., 2012
Stimulants Methamphetamine 3–18 h N27 dopaminergic
cells
Impaired proteasome activity Lin et al., 2012
Methamphetamine Acute injection Rat striatum Increase in Ubiquitin C-terminal
hydrolase L-1 and decrease in RN3
subunit
Iwazaki et al., 2006
Methamphetamine 24–48 h Rat striatum and
frontal cortex
Transient decrease in 26S proteasome
activity
Dietrich et al., 2005
Methamphetamine 8 days Rat frontal cortex Increase in Ubiquitin C-terminal
hydrolase L-1 and decrease
Faure et al., 2009
in α1, α2 and regulatory 6A subunits
(Continued)
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Table 1 | Continued
Drug class Drug Treatment Cell type/Species Molecular/cellular effects Reference
Amphetamine 7 days +
withdrawal
Rat striatum PSD UPS-dependent degradation of Shank
and GKAP
Mao et al., 2009
Cocaine CPP Rat medial prefrontal
cortex
Increase in Ubiquitin-conjugating
enzyme E2N, α2 and regulatory
p45/SUG subunit
Guan and Guan, 2013
Cocaine 24–48 h Rat striatum and
frontal cortex
Transient increase in 26S proteasome
activity
Dietrich et al., 2005
Cocaine CPP Rat Nacc core UPS-dependent degradation of NSF
protein
Ren et al., 2013
Ethanol Ethanol 5 days Mouse cortical
neurons
Decrease in the mRNA of
Ubiquitin-conjugating enzymes E2 and
E3A, Ubiquitin specific protease 9, and 7
regulatory or catalytic subunits
Gutala et al., 2004
Ethanol 4 months, drinking
water
Mouse cortex Impairment of UPS activity associated
with an increase in
immunoproteasome subunits
Pla et al., 2014
Nicotine Nicotine 17 h HEK cells, rat cortical
neurons
Reduced ERAD-dependent degradation
of α4β2 nicotinic acetycholine receptors
Govind et al., 2012
Nicotine 8 h Recombinant HELA
cells
Reduced ERAD-dependent degradation
of α3β4 nicotinic acetycholine receptors
Mazzo et al., 2013
Nicotine 14 days Rat prefrontal cortex Increase in the mRNA of several
Ubiquitin-conjugating enzymes,
Ubiquitin proteases, and regulatory and
catalytic subunits of the proteasome
Kane et al., 2004
Nicotine 14 days Rat medial basal
hypothalamus
Decrease in the mRNA of several
Ubiquitin-conjugating enzymes and α
subunits
Kane et al., 2004
Nicotine 14 days Mouse dopaminergic
neurons
Increase in the mRNA of the E2
ubiquitin-conjugating enzyme E2J2,
decrease in that of PSME2 regulatory
subunit and Ubiquitin specific proteases
16 and 34
Henley et al., 2013
Nicotine 24 h Mouse prefrontal
cortex
Inhibition of UPS associated with
increased glutamate receptor subunits
and PSD95
Rezvani et al., 2007
Cannabinoids 9-THC 48h Human astrocytes Increase in the mRNA of Ubiquitin
specific protease 3
Bindukumar et al.,
2008
HU-210 16 h Neuro-2A cells UPS-dependent degradation of
Rap1GAPII resulting in neurite outgrowth
Jordan et al., 2005
that of ubiquitin and Ubiquitin-conjugating enzyme 7 increase in
the white matter of the brain of alcoholic patients (Alexander-
Kaufman et al., 2006; Kashem et al., 2007). Again at the mRNA
level, chronic treatment of rats with nicotine produces an elevated
expression of ubiquitin-conjugating enzymes, proteasome regu-
latory and catalytic subunits and DUBs in the prefrontal cortex
whereas their level is decreased in the medial basal hypothala-
mus (Kane et al., 2004). Variations can be of opposite direction
within a single cell type with for example an up-regulation
of the E2 ubiquitin-conjugating enzyme E2J2 associated with
the down-regulation of a proteasome regulatory subunit and
two DUBs in mouse dopaminergic neurons chronically treated
with nicotine (Henley et al., 2013). Finally an up-regulation of
the DUB Ubiquitin specific protease 3 was observed in human
astrocytes exposed for 48 h to 9-THC (tetra-hydro-cannabinol)
(Bindukumar et al., 2008).
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All drugs of abuse can thus affect the expression and abun-
dance of key UPS proteins. However, the data reported above
are only descriptive. Moreover, UPS components are affected
differently depending on the drug type, its method of adminis-
tration, the duration of the treatment and the cell type or brain
region considered (Table 1). Complementary studies have also
found that drugs of abuse modify the activity of the UPS in
parallel with changes in the expression of its various compo-
nents. Indeed morphine was demonstrated to inhibit the activity
of the 20S proteasome in human neuroblastoma cells, with neu-
roprotective consequences (Rambhia et al., 2005). On the con-
trary, PKC-dependent inhibition of the UPS was linked to the
autophagy-mediated toxicity of methamphetamine in dopamin-
ergic neurons (Lin et al., 2012). In addition it has been pro-
posed that the higher toxicity of methamphetamine compared
to cocaine was due to its long inhibitory effect on protea-
some activity (Dietrich et al., 2005). Finally, a recent study
demonstrated that chronic ethanol induces toxicity in mice
through a Toll-like receptor 4-dependent impairment of the
UPS (Pla et al., 2014). This deleterious effect could depend on
a shift in proteasome composition from classical to immuno-
proteasome subunits, a phenomenon known to play a role in
the neurotoxicity observed in neurodegenerative diseases, and
on an increase in chymotrypsin-like and trypsin-like activities
(Pla et al., 2014).
So far we have only described global changes in the com-
position and/or activity of the UPS associated with beneficial
or deleterious effects on the functioning or survival of neurons.
However, more subtle and finely regulated mechanisms need to
be considered to explain the plasticity phenomena underlying the
development of addiction-related behaviors. These mechanisms
do not necessarily imply a global modification of UPS activity
but rather the degradation of specific targets in precise cellular
locations. Unfortunately fewer studies have focused more specif-
ically on synaptic and/or signaling proteins degraded by the UPS
in relation with the administration of drugs of abuse.
UPS TARGETS INVOLVED IN DRUG-INDUCED PLASTICITY
Drugs of abuse target receptors, channels and transporters located
in the plasma membrane. However, membrane proteins are not
typical proteasome substrates but are rather degraded in lyso-
somes. Proteasome-mediated degradation only occurs for mis-
folded membrane proteins through the ERAD (Endoplasmic-
reticulum-associated protein degradation) pathway before their
export to the plasma membrane (Christianson and Ye, 2014)
but ubiquitination can also modulate the degradation of mem-
brane proteins after endocytosis by influencing their sorting to
lysosomes through the ESCRT (endosomal sorting complexes
required for transport) system (Macgurn et al., 2012). This phe-
nomenon involves HECT (Homologous to the E6-AP Carboxyl
Terminus) E3 ligases and will not be discussed in detail here
since it is proteasome-independent. However, it is worth men-
tioning that, since proteasome inhibitors cause the accumulation
of ubiquitinated proteins and thus reduce the available pool
of free ubiquitin, they can affect indirectly ubiquitin-dependent
proteasome-independent processes such as sorting to lysosome
(Mimnaugh et al., 1997).
Mu opioid (MOP) receptors play a role in the rewarding and
reinforcing properties of opioids but also of most non-opioid
abused drugs (Le Merrer et al., 2009). They are ubiquitinated
following activation. Proteasome inhibitors increase their basal
abundance and decrease agonist-induced down-regulation in
recombinant cells (Chaturvedi et al., 2001). The increase in basal
receptor expression following proteasome inhibition could be due
to the blocking of the ERAD pathway whereas the reduction in
agonist-induced down-regulation could result from the indirect
effect of proteasome inhibitors on ubiquitin-dependent sorting to
lysosomes. Indeed it was recently shown that the ubiquitination
of the first intracellular loop of the MOP receptor facilitates its
lysosomial degradation by promoting its transfer to intralumenal
vesicles downstream of the ESCRT system (Hislop et al., 2011). It
was also proposed that different translational forms of the recep-
tor showed different sensitivities to the ERAD pathway because
of additional ubiquitination sites (Song et al., 2009). Besides the
MOP receptor, the nicotinic receptor is another example of drug
target which has been shown to be regulated by the UPS. Here
again the ERAD pathway seems to be involved and the subunit
composition of pentameric nicotinic receptors has an influence
on their sensitivity to this pathway (Govind et al., 2012; Mazzo
et al., 2013).
UPS-dependent changes have also been identified downstream
of receptor activation. In SH-SY5Y human neuroblastoma cells,
long-term morphine treatment induces proteasome-dependent
degradation of the Gβ subunit of heterotrimeric G proteins
(Mouledous et al., 2005). This degradation could reduce G
protein-coupled receptor signaling and restore the activity of
effectors normally inhibited by Gβ subunits such as adenylyl
cyclase. In the same cells, opioids have also been shown to
induce the ubiquitination and degradation of regulator of G pro-
tein signaling 4 (RGS4), a protein that controls the duration of
G protein signaling by acting as a GTPase accelerating protein
(GAP) (Wang and Traynor, 2011). RGS4 is an unstable protein
known to be subjected to the N-end rule pathway, a particu-
lar type of regulation based on the removal of the N-terminal
methionine and the arginylation of the resulting N-terminal cys-
teine to promote ubiquitination and proteasome degradation.
Its down-regulation affects the signaling of other G protein-
coupled receptors present in the same cell. Overall, by regulating
the abundance of several signaling molecules sensitive to opi-
oid treatment, the UPS participates in the homeostatic processes
involved in the development of opioid tolerance and depen-
dence (Bailey and Connor, 2005; Christie, 2008). In mice, chronic
morphine treatment induces a decrease in the total amount of
ubiquitinated proteins in the striatum. In parallel, the heat-shock
protein HSP70 was shown to be overexpressed, probably because
of a lower ubiquitination rate (Yang et al., 2014). The higher
expression of this protein could participate in the behavioral
sensitization induced by morphine (Qin et al., 2013). However,
the HSP70 cellular effect mediating this process is currently
unknown. Besides changes in signaling, long-term drug treatment
is known to affect neuronal structural plasticity (Robinson and
Kolb, 2004). Small G proteins can influence cellular architecture
and it is thus significant to note that, in neuro-2A cells, cannabi-
noids induce neurite outgrowth by activating the small G protein
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Rap1 through the proteasome-dependent degradation of one of
its GAP, Rap1GAPII (Jordan et al., 2005).
The neuronal adaptations described so far are homeo-
static non-associative phenomena. They result from the direct
activation of the drug target and its downstream signaling and
are not sufficient to explain the associative processes involved in
addiction. Similarly to classical forms of memory, drug addic-
tion involves activity-dependent plasticity at excitatory synapses
within neuronal circuits, notably those controlling motivated
behaviors (Kauer and Malenka, 2007; Russo et al., 2010).
Following drug administration, the UPS system regulates the
abundance of several proteins at the glutamatergic synapse but
very few studies have identified these proteasome targets. In
the case of opioids, an increase in ubiquitinated proteins in
the synaptosomal fraction of the mouse Nacc was observed fol-
lowing morphine conditioning (Massaly et al., 2013) but the
identity of the UPS targeted proteins was not reported. So far,
the only glutamate-related proteins shown to be degraded by
the proteasome following chronic morphine treatment are gluta-
mate transporters EAAC1, GLSAT, and GLT-1 but these changes
were observed in the rat spinal cord and were related to anal-
gesic tolerance rather than addiction (Yang et al., 2008a,b).
Concerning nicotine, one study addressed the effect of its intra-
peritoneal injection in mice on the expression of synaptic pro-
teins (Rezvani et al., 2007). It suggested that the observed
increase in the amount of GluR1 α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPA) receptor subunits, NR2A
NMDA receptor subunits, metabotropic receptor mGluR1α, and
PSD95 (a scaffolding protein of the PSD), but also the decrease
in the quantity of Shank (another scaffolding protein), were due
to an inhibition of proteasome activity. The exposure to stimu-
lants was also reported to have UPS-dependent synaptic effects.
NAC1 (nucleus accumbens-associated protein 1), the product
of an immediate early gene up-regulated by psychostimulants,
takes part in the recruitment of the proteasome to the PSD
by interacting with Cullin-based E3 ubiquitin ligases and the
19S ATPase subunit Mov34 (Shen et al., 2007). The UPS could
also contribute to the phenomenon of synaptic scaling that is
observed in the Nacc following cocaine withdrawal and results
from the addition of AMPA receptors to the synapse (Sun and
Wolf, 2009). UPS-dependent synaptic changes in the striatum
have been shown to contribute to the behavioral sensitization
induced by repeated amphetamine injections in rats. Contrarily
to acute nicotine injection, chronic amphetamine treatment pro-
duced a decrease in NMDA receptor subunits and anchoring
proteins in the PSD. Only Shank and GKAP (guanylate-kinase-
associated protein) were ubiquitinated and it was proposed that
the degradation of these important anchoring proteins indirectly
leads to a loss of PSD95 and NR1 and NR2B subunits of the
NMDA receptor at the synapse (Mao et al., 2009). Finally, the
retrieval of cocaine place preference in rats has been shown to
result in an increase in protein poly-ubiquitination in the core
of the Nacc, and in particular in the degradation of NSF (N-
ethylmaleimide-sensitive fusion), a protein of the PSD involved
in synaptic plasticity (Ren et al., 2013). In conclusion, the UPS
is involved in the synaptic plasticity that underlies some of the
behavioral adaptations to drug exposure. However, the molecular
details are still poorly known and will probably depend on
the drug type, the location of the synapse in the neuronal cir-
cuit and the phase of the addiction process under study. It is
thus critical to implement studies to establish direct causal rela-
tionship between the degradation of neuronal proteins by the
UPS in a particular brain region and a given addiction-related
behavior.
UPS AND ADDICTION-RELATED BEHAVIORS
Few studies have assessed the role of protein degradation by
the proteasome in drug-related behaviors. Recently we found
that UPS function in the Nacc is crucial in several types of
opioid-induced behaviors (Massaly et al., 2013). Our goal was
to assess the role of protein degradation by the proteasome in
the development of drug seeking behaviors and the motivation to
obtain opioids. By using proteasome inhibitors our study demon-
strated a clear role of the UPS in the Nacc during acquisition of
non-operant tasks, namely CPP and context-dependent locomo-
tor sensitization in mice. Intra-Nacc proteasome inhibitors also
prevented the acquisition of operant tasks in mice (intra-VTA
self-administration) and rats (intra-venous self-administration).
However, these behavioral paradigms do not enable us to clearly
discriminate between an effect of proteasome inhibitors on
drug-induced memory and on non-associative drug effects. The
behavioral sensitization procedure can be implemented in a
context-dependent or -independent way (Valjent et al., 2006).
Figures 2A–C shows the comparison between the effects of pro-
teasome inhibition in a context-dependent (Massaly et al., 2013)
and a context-independent paradigm. In both experiments mice
were submitted to 5 daily morphine injections followed by a
2 day withdrawal period. On day 1 basal horizontal activity
was measured during 1 h directly after i.p. morphine injection
(Figures 2B,C, empty bars). On days 2, 3, 4, and 5 mice received
intra-Nacc injection of DMSO or the proteasome inhibitor lac-
tacystin 1 h prior to i.p. morphine treatment and were then
directly placed in their home cage to prevent association between
drug and cues present in activity boxes (context-independent,
Figure 2C) or in activity boxes (context-dependent, Figure 2B).
Three days after the last opioid treatment, animals were chal-
lenged with an i.p. morphine injection and locomotor activity was
measured during 1 h to assess behavioral sensitization. Control
groups showed a significant locomotor sensitization on day 8
(Figures 1C, 2B, DMSO group). Lactacystin injections prevented
behavioral sensitization only in the context-dependent procedure
(Figure 2B). It thus appears that the UPS in the Nacc is not
necessary for the development of behavioral sensitization when
this adaptation is context-independent (Figures 2A–C, refer to
(Massaly et al., 2013) for details). This result, together with the
fact that intra-Nacc injection of proteasome inhibitors prevents
the consolidation of morphine place preference, strongly suggests
that UPS activity in the Nacc is involved in drug-context associ-
ation rather than non-associative motivational effects of opioids.
However, this distinction might not be true for each type of drug
of abuse and in particular for stimulants. Indeed, proteasome
inhibitors have been shown to inhibit the development of behav-
ioral sensitization to amphetamine after intra-Nacc injection in
rats in a context-independent paradigm (Mao et al., 2009).
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FIGURE 2 | UPS involvement in behavioral sensitization and
reconsolidation of morphine place preference. (A) Schematic
representation of the protocol followed in context-dependent and
-independent locomotor sensitization. The morphine dose was 10mg/kg.
(B) UPS inhibition blocks the acquisition of behavioral sensitization when a
context-dependent paradigm is used (lactacystin 100 pmol in 0.5μl per side:
n = 8 and DMSO: n = 11), (C) whereas it does not affect this drug-adaptation
in a context-independent procedure (lactacystin: n = 6 and DMSO: n = 8).
Data are expressed in number of beam breaks ± SEM during a 1 h session
(Continued)
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FIGURE 2 | Continued
after morphine injection before (day 1; empty bars) and after conditioning
(day 8; black bars). Two-Way ANOVA followed by Bonferroni post-hoc
tests: n.s., non-significant; ∗∗∗p < 0.001. (D) Schematic representation of
the protocol used for assessing the role of the UPS in reconsolidation.
(E) Intra-Nacc bilateral injection of lactacystin 1 h before a drug-context
re-exposure abolishes drug-induced place preference when tested 24 h
after this new association (n = 6) whereas DMSO treated-animals still
express place preference (n = 6). Data are expressed as percentage of
time spent in the drug-associated compartment ± SEM during
pre-conditioning tests (empty bars) and post-conditioning tests (filled
bars). Two-Way ANOVA followed by Bonferroni post-hoc tests: n.s.,
non-significant; ∗p < 0.05. See Massaly et al. (2013) for details about
behavioral procedures.
Consolidation is the process by which stable long-term mem-
ories are formed following a learning session. Reconsolidation
refers to the fact that the memory trace can return to an active
labile state after recall (Alberini and Ledoux, 2013). Interfering
with this process could thus offer a way to erase drug-context
association with important therapeutic consequences. If lacta-
cystin is injected in the Nacc before a new drug-compartment
association performed 1 week after the last morphine place pref-
erence conditioning (Massaly et al., 2013, Figure 2D), mice do
not display any place preference for the morphine compartment
on the following day, contrarily to the DMSO control group
(Figure 2E). The UPS in the Nacc thus seems to be involved in
reconsolidation of place preference induced by morphine. Our
conclusions concerning the involvement of the UPS in consoli-
dation and reconsolidation of drug-associated memories are only
partly consistent with those of the only other study examining
this question (Ren et al., 2013). Ren et al. found that inhibiting
UPS activity in the Nacc interfered with drug-reward memories
using cocaine CPP in rats. However, in their model, proteasome
inhibitors blocked CPP extinction when injected following each
extinction session but were not efficient on memory consolida-
tion during the learning phase. Moreover, they did not interfere
directly with memory reconsolidation following a reactivation
session but counteracted the inhibitory effect of protein synthesis
inhibition on this process. These apparent discrepancies are likely
due to many differences in experimental conditions between the
two studies: animal model (rats vs. mice), drug type (cocaine vs.
morphine), conditioning procedure (4 drug/saline injections over
8 days vs. 3 injections over 3 days), timing of injection of protea-
some inhibitors (before vs. after memory reactivation), method of
induction of memory reconsolidation (reactivation in the absence
vs. in the presence of drug). Taken together, the two studies con-
firm that the UPS in the Nacc plays a key role in drug-reward
memories although further work is needed to fully understand
under which exact circumstances it is recruited.
In conclusion, even if some discrepancies can be observed
between studies depending on the model under investigation, it
appears that the UPS plays a role in drug-related behaviors and
the adaptation to the exposure to drugs of abuse. Future work
will certainly bring us new evidence to complete the picture of the
involvement of proteasome-dependent protein degradation in the
brain during addiction.
FUTURE DIRECTIONS
It is clear from the studies reviewed here that the UPS plays
an essential role in neuronal plasticity associated with long-
term exposure to drugs of abuse. However, the UPS is involved
in so many cellular processes that we are still a long way
from understanding its specific contribution to each aspect of
drug use and abuse. Several outstanding questions need to be
addressed to achieve this goal. What are the most significant
cellular targets of the UPS during neuronal plasticity associated
with drug addiction? So far, studies have focused on synap-
tic and signaling proteins but other types of proteins, such as
for example transcription factors, are mandatory for enduring
neuronal plasticity and could be regulated directly or indi-
rectly by UPS-dependent processes (Carle et al., 2007; Dong
et al., 2008). Where does the regulation take place? All the
behavioral studies reported here focused on the Nacc but dif-
ferent UPS-dependent changes will probably occur depending
on the brain region. Also alterations in protein content will
vary according to the type of plasticity occurring in each indi-
vidual neuron or synapse. When does the protein need to be
degraded? Different UPS targets will be concerned depending
on the phase of the addiction process. For example changes
appearing along the course of drug administration will probably
differ from those resulting from withdrawal. Why is a UPS-
dependent regulation occurring? In particular it will be impor-
tant to distinguish homeostatic regulations involved in non-
associative tolerance or sensitization from more integrated plas-
ticity phenomena responsible for associative context-dependent
aspects of addiction. How are the proteins targeted to the pro-
teasome? Identifying the mechanism by which each important
UPS substrate is targeted to the proteasome (post-translational
modification preceding ubiquitination, type of E3 ligase. . . ) will
offer opportunities to control addiction-related processes more
specifically than by blocking the catalytic activity of the protea-
some. Many technical limitations may prevent us from answer-
ing fully to these questions but the link between the control
of protein expression through UPS-dependent degradation and
plastic changes involved in addiction clearly deserves further
investigation.
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